Latest news

• Myovant preps US filing for relugolix in prostate cancer

  Takeda-partnered drug had 97% response rate in advanced prostate cancer. Myovant is locked in a battle with AbbVie for women’s health applications of its GnRH inhibitor relugolix, but a ... The phase 3 HERO trial of Takeda-partnered relugolix has

• AbbVie files blockbuster hopeful elagolix for uterine fibroids

  However, AbbVie is facing some competition in the category from Myovant’s rival drug relugolix, which has just chalked up positive phase 3 trials in uterine fibroids and will set up ... Phil Nadeau – thinks it can and that relugolix will become a $1bn

• Myovant has second phase 3 trial to back its uterine fibroids drug

  Aims to take on AbbVie in new market. Myovant now has two phase 3 trials supporting its relugolix candidate for uterine fibroids, setting up a regulatory filing in the US before ... Myovant is banking on the convenience of once-daily dosing with relugolix

• Myovant’s fibroids drug clears phase 3 trial, but shares sink

  still to report and relugolix filing will likely be several months behind elagolix. ... In Myovant’s favour is that relugolix is also already on the market in Japan, where it is sold by Takeda.

• Urovant slips on phase 3 incontinence drug data

  Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.